SAPHNELO (Anifrolumab), a monoclonal antibody for moderate-to-severe systemic lupus erythematosus (SLE), demonstrates robust clinical efficacy by targeting type I interferon receptors. Approved in over 70 countries, it generated $483 million in sales in the first nine months of 2025, driven by a shift toward biologic therapies and high unmet medical needs in SLE. Despite a recent FDA request for more data on its subcutaneous form, AstraZeneca is actively addressing regulatory concerns. The market forecast through 2034 anticipates continued growth and expanded indications globally.
AstraZeneca's investigational oral GLP-1 receptor agonist, elecoglipron, demonstrated significant weight loss and improved diabetes control in two Phase 2b trials. The VISTA study showed an average weight reduction of up to 11.8% in obese or overweig...
This monthly series highlights five large-cap, dividend-paying stocks trading at significant discounts compared to their historical norms, selected from over 7,500 U.S.-listed companies. The primary list offers an average yield of 4.2%, with two addi...
